Wei Lin 4
4 · Revolution Medicines, Inc. · Filed Jun 20, 2024
Insider Transaction Report
Form 4
Wei Lin
Chief Medical Officer
Transactions
- Sale
Common Stock
2024-06-17$37.39/sh−5,589$208,954→ 70,851 total
Footnotes (4)
- [F1]Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.
- [F2]This transaction was executed in multiple trades in prices ranging from $37.3867 to $37.3871, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]Includes 2,040 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2024.
- [F4]Includes 59,250 RSUs.